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Context: Mechanisms linking high and high-normal thyroid function to an increased 
cardiovascular risk remain unclear. Hypothetically, coagulation can play a role. 
Objective: To investigate: (i) the association of thyroid function with coagulation factors, (ii) 
whether coagulation factors mediate the association of thyroid function with cardiovascular 
disease (CVD). 
Design and Setting: Rotterdam Study, a population-based, prospective study 
Participants and Main outcome measurements: In 5918 participants (mean age, 69.1 years), 
we measured thyrotropin, free thyroxine (FT4) and coagulation factors (von Willebrand factor 
antigen [VWF:Ag], ADAMTS13 activity, fibrinogen). Participants were followed for the 
occurrence of cardiovascular events and deaths. Associations of thyroid function 
with coagulation factors (standardized Z scores) and CVD were assessed through linear 
regression and Cox-proportional hazard models, adjusted for potential confounders. We 
performed causal mediation analyses to evaluate if th  effect of thyroid function on CVD is 
mediated by coagulation. 
Results: Higher FT4 levels were associated with higher VWF:Ag (β=0.34; 95% confidence 
interval [95%CI]=0.22,0.47), lower ADAMTS13 activity (β=-0.22; 95%CI=-0.35,-0.09), and 
higher fibrinogen (β=0.26; 95%CI=0.13,0.39). 857 incident cardiovascular events and 690 
cardiovascular deaths occurred. FT4 levels were positively associated with cardiovascular 
events and deaths. The effect of FT4 on incident cardiovascular events was minimally 
mediated by fibrinogen (1.6%), but not by VWF:Ag and ADAMTS13. VWF:Ag and 
fibrinogen together mediated 10.0% of the effect of FT4 on cardiovascular deaths.  
Conclusions: Higher FT4 levels were associated with higher VWF:Ag, lower ADAMTS13 
activity and higher fibrinogen, indicating a procoagulant state. VWF:Ag and fibrinogen 
explained up to 10% of the link between FT4 with CVD.  
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This study investigated whether coagulation factors mediate the role of thyroid function on 
cardiovascular disease. VWF:Ag and fibrinogen partly explained the link of FT4 with cardiovascular 
disease. . 
Introduction 
The cardiovascular system is one of the major targes of thyroid hormone action. Thyroid 
hormones affect cardiomyocytes by stimulating the ion channels in the cell membranes and 
by binding to the nuclear thyroid hormone receptors, further promoting the expression of 
target genes.(1) Thyroid hormones also influence the cardiovascular system by affecting the 
sympathetic nervous system and the peripheral circulation.(1) To date, population-based 
studies among middle-aged and older adults have shown that high and high-normal thyroid 
hormone levels are associated with an increased risk of cardiovascular disease and mortality, 
independent of traditional cardiovascular risk factors as hyperlipidemia, hypertension, 
diabetes, and obesity.(2-4) This points towards other factors that can mediate the increased 
cardiovascular risk in case of excess thyroid hormones. The identification of these mediating 
factors is essential to better understand the role of thyroid hormones in cardiovascular 
disease, as well as to identify potential targets for future preventive strategies.   
Hemostasis may be one mechanism through which thyroid hormones affect 
cardiovascular system. In vitro and in vivo studies have shown that thyroid hormones directly 
regulate the transcription of genes encoding coagulation proteins in the hepatic and 
endothelial cells (5-8) (6,9,10). In turn, coagulation proteins, such as von Willebrand factor 
(VWF), ADAMTS13 (a disintegrin and metalloprotease with thrombospondin motif repeats 
13), and fibrinogen have been associated with an increased risk of coronary heart disease 
(CHD), ischemic stroke(11-14) and cardiovascular motality.(15) VWF mediates platelet 
adhesion and aggregation, which play an important role in thrombus formation.(16) 
ADAMTS13 cleaves the procoagulant VWF multimers into smaller, less procoagulant 
multimers.(17) Fibrinogen is converted into fibrin, which strengthens the clot structure of the 
thrombus. Despite the clear role of coagulation factors on cardiovascular system, it has never 
been investigated whether and to what extent coagulation factors mediate the association of 
thyroid function with cardiovascular disease and mortality. To date, observational and 
experimental studies have established an increased risk of bleeding in hypothyroidism and an 
increased risk of thrombosis in hyperthyroidism.(18,19) However, previous studies have not 
investigated whether the anticoagulant effects of hypothyroidism and the procoagulant effects 
of hyperthyroidism are extended even within the normal reference range of thyroid function.  
In this large prospective population-based cohort study, we aimed to: (i) assess the 
association of thyroid function with VWF, ADAMTS13, and fibrinogen; and (ii) investigate 
whether and to what extent these coagulation factors mediate the association of thyroid 
function with cardiovascular events and deaths. 
Methods 
Study population 
This study was embedded within the framework of the Rotterdam Study, a large prospective 
population-based cohort study among the residents of Ommoord, a district of Rotterdam, the 
Netherlands. The objectives and study design have been extensively described elsewhere.(20) 
The Rotterdam Study was initiated in 1989, including 7983 participants aged 55 years or 
older. In 2000, the study was extended with a second hort of 3011 subjects. Study 
participants undergo extensive follow-up medical examinations every 3 to 5 years. Baseline 
measurements for the present study were performed during the third visit of the first cohort 
(RS I.3, 1997-1999, n=4797) and the first visit of he second (RS II.1, 2000-2001, n=3011) 
cohort of the Rotterdam Study. A total of 6140 participants had data available on thyroid 
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function measurements, VWF:Ag, ADAMTS13 activity, and fibrinogen levels. Of these, 
5918 were followed for the occurrence of cardiovascular events and deaths. Participants with 
thyroid function measurements, coagulation data, and complete information on prevalent 
cardiovascular disease and mortality, were eligible.  
The protocols of the Rotterdam Study have been approved by the Medical Ethics 
Committee of the Erasmus University and by the Ministry of Health, Welfare and Sport of 
the Netherlands, implementing the Population Study Act Rotterdam Study. In accordance 
with the Declaration of Helsinki, all included participants provided written informed consent 
to participate in the study and to obtain information from their treating physicians. 
Assessment of thyroid parameters 
Thyroid function was assessed during the third visit of the first cohort (RS I.3) and the first 
visit of the second (RS II.1) cohort using the same method and assay. Measurements of TSH, 
and FT4, were performed in baseline serum samples stored at -80°C using the 
electrochemiluminescence immunoassay “ECLIA” Roche (Roche Diagnostics International 
Ltd, Rotkreuz Switzerland). The reference ranges of TSH (0.40 to 4.0 mIU/L) and FT4 (0.86 
to 1.94 ng/dL, alternatively 11 to 25 pmol/L) were d termined based on national guidelines 
and our previous studies.(20) Precision was determined using Elecsys reagents, pooled 
human sera, and controls in a modified protocol of the Clinical and Laboratory Standards 
Institute. The intra- and inter-assay coefficients of variations were ≤8.7% for TSH and ≤4.8% 
for FT4. Thyroid peroxidase antibodies (TPOAbs) were assessed with the 
electrochemiluminescence immunoassay Roche for TPOAbs. TPOAbs >35 kU/ml were 
considered as positive, as recommended by the assaymanufacturer.  
Assessment of coagulation factors 
Von Willebrand factor antigen (VWF:Ag) levels were measured via in-house ELISA, using 
polyclonal rabbit anti-human VWF antibodies (DakoCytomation, Glostrup, Denmark) for 
catching and tagging. ADAMTS13 activity was measured in a kinetic assay using the 
Fluorescence Resonance Energy Transfer Substrate VWF 73 assay.(21) Fibrinogen levels 
were derived from the clotting curve of the prothrombin time assay using thromborel S as a 
reagent in an automated coagulation laboratory (ACL 300 Instrumentation Laboratory). 
VWF:Ag, ADAMTS13 activity, and fibrinogen levels were measured against a reference 
curve of serial dilutions of normal human plasma, calibrated against the international 
standard (Siemens).(22) 
Assessment of cardiovascular disease 
Cardiovascular events were defined as fatal and nonfatal myocardial infarction, other CHD 
mortality, or stroke, as previously described.(23) Prevalent cardiovascular disease was 
defined as history of myocardial infarction, stroke, coronary or other arterial 
revascularization.(23,24) Prevalent cardiovascular disease was assessed through interview 
and verified in medical records. Data on incident cardiovascular events were collected 
through linkage of the study database with files from general practitioners and hospital 
records.  Cardiovascular mortality was defined as death due to CHD, cerebrovascular disease 
or other cardiovascular diseases, as previously describ d.(2,23) The ascertainment of 
cardiovascular mortality in the Rotterdam Study has been extensively described in a previous 
study.(23) In short, information on cardiovascular mortality is obtained from municipality 
records, general practitioners and reports of medical specialists. As a first step, all deaths in 
the Rotterdam Study are adjudicated based on ICD-10 codes. Furthermore, two research 
physicians review all the available clinical information, and ascertain independently the 
underlying cause of death. All cases are subsequently r viewed and validated by a medical 
specialist. 
Additional measurements 
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The baseline home interview provided information on medical history, medication use, 
tobacco smoking, and alcohol consumption.(20) Smoking habits were categorized as current, 
former and never smoking. Serum glucose and lipid levels were measured using automatic 
enzymatic procedures (Roche Diagnostics GmbH, Mannheim, Germany). Anthropometric 
measurements were performed in the research center by rained medical staff. Body mass 
index was calculated as weight in kilograms divided by height in meters squared. Blood 
pressure was measured in the sitting position on the right arm and calculated as the mean of 
two measurements using a random-zero sphygmomanometer. Diabetes mellitus was defined 
as fasting serum glucose level of 7 mmol/L or more, non-fasting plasma glucose level of 11.1 
mmol/L or more (when fasting samples were absent) or the use of antidiabetic medications. C 
reactive protein was measured in nonfasting serum sa ples that had been kept frozen at -
20°C by use of Rate Near Infrared Particle Immunoassay (Immage Immunochemistry 
System; Beckman Coulter). Blood group antigen phenotypes were reconstructed by 
haplotypes analysis of 4 single nucleotide polymorphisms rs687289, rs507666, rs8176704, 
and rs8176749, which served as tagging single nucleotide polymorphisms for the O, A1, A2, 
and B alleles. Occurrence of cancer was determined through general practitioners and by 
linkage with a nationwide registry of histopathology and cytopathology in The Netherlands, 
Pathologisch-Anatomisch Landelijk Geautomatiseerd Archief (PALGA). Two research 
physicians independently assessed the first date and di gnosis of cancer. Cancer events were 
classified according to the international classification of diseases 10th edition. In case of 
discrepancy, consensus was sought or a cancer epidemiologist decided. 
Statistical analysis 
The associations of thyroid function (TSH and FT4) with coagulation factors (ie, VWF:Ag, 
ADAMTS13 activity, and fibrinogen levels) were assed by using linear regression models. 
βs were estimated per 1 standard deviation (sd) increase for VWF:Ag, ADAMTS13 activity, 
and fibrinogen levels. Associations of thyroid function and coagulation factors with incident 
cardiovascular events and cardiovascular deaths were assessed through Cox-proportional 
hazard models. We used restricted cubic splines to acc unt for nonlinearity of the 
associations, but no evidence of nonlinearity was observed. Analyses were adjusted for 
potential confounders that were selected based on biological plausibility and previous 
literature. Model 1 was adjusted for age, sex, and cohort. Model 2 was adjusted for age, sex,  
cohort, smoking, alcohol intake, body mass index, diabetes, total cholesterol, triglycerides, 
systolic blood pressure, use of antihypertensive or lipid-lowering medications, anticoagulant 
medications and ABO blood group (O vs non-O). For the analyses in which coagulation 
factors were the exposure and cardiovascular outcomes were the outcome, we additionally 
adjusted for TSH and FT4 levels. 
To examine the robustness and applicability of our results, we performed several 
sensitivity analyses on the association between thyroid function and coagulation factors. (I) 
To account for the potential influence of inflammation and thyroid autoimmunity, we 
additionally adjusted our analyses for C reactive protein levels and TPOAb positivity, 
respectively. Moreover, we investigated the associati n of TPOAb positivity with coagulation 
factors. (II) We additionally adjusted our analyses for prevalent cardiovascular disease. (III) 
Thyroid hormones have been associated with the risk of cancer, which is in turn characterized 
by a hypercoagulable state.(25) To exclude any potential bias caused by presence of cancer, 
we excluded participants with cancer at baseline (n=292). (IV) We restricted the analysis to 
participants with thyroid function within the reference range, without past thyroid disease and 
not using thyroid medications. (V) To test for potential effect modification, we added product 
interaction terms of the exposure with covariates in the multivariable model. (VI) Due to the 
biological interaction between VWF and ADAMTS13, wealso investigated the association of 
thyroid function with the combination of VWF:Ag levls and ADAMTS13 activity. We 
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grouped participants into 9 categories, based on the combinations of VWF:Ag tertiles and 
ADAMTS13 tertiles. Furthermore, we performed multinomial logistic regression to evaluate 
the association between FT4 levels and the 9 combinations of VWF:Ag tertiles and 
ADAMTS13 tertiles. Individuals who were in the lowest tertile of VWF:Ag and in the 
highest tertile of ADAMTS13 (category with lowest thrombotic risk) were considered as 
reference.  
We performed a causal mediation analysis, which evaluated whether the effect of FT4 on 
incident cardiovascular events and cardiovascular de ths was mediated by coagulation factors 
(Figure 1). The following paths were tested: the dir ct effect (effect of the exposure on the 
outcome through pathways other than the mediator); the indirect effect (effect of the exposure 
on the outcome via the mediator); the total effect (the sum of direct effect and indirect effect); 
the proportion mediated (indirect effect/total effect). To test for mediation effects, we used 
conditional process analysis techniques as described by Hayes.(26) Statistical analyses were 
conducted using SPSS version 21.  
Results 
Baseline characteristics of 5918 eligible participants are shown in Table 1. The mean age was 
69.1 years (sd, 8.2) and 56.7% were women (Table 1). During a median follow-up of 11.3 
(interquartile range, 10.0 to 12.7) years, 857 incident cardiovascular events and 690 
cardiovascular deaths occurred.  
Thyroid function and coagulation factors 
Higher FT4 levels were associated with higher VWF:Ag (β, 0.34; 95% confidence interval 
[95% CI], 0.22 to 0.47, per 1ng/dl increase in FT4), lower ADAMTS13 activity (β,-0.22; 95% 
CI, -0.35 to -0.09, per 1ng/dl increase in FT4), and higher fibrinogen levels (β, 0.26; 95% CI, 
0.13 to 0.39, per 1ng/dl increase in FT4) (Table 2). Overall, TSH was not consistently 
associated with any of the coagulation factors (Table 2). Results remained consistent after 
additionally adjusting for C reactive protein, TPOAb, prevalent cardiovascular disease, and 
after excluding participants with cancer at baseline. No evidence of effect modification was 
observed. TPOAb positivity was not associated with VWF:Ag, ADAMTS13 activity, or 
fibrinogen (β, -0.01, 95% CI, -0.08 to 0.06; β, -0.02, 95% CI, -0.10 to 0.05; β, -0.03, 95% CI, 
-0.10 to 0.04, respectively). Results remained similar or became stronger after restricting the 
analyses to euthyroid participants (Table 2).  
In a sensitivity analysis, we investigated the association of FT4 levels with the 9 
combinations of ADAMTS13 tertiles and VWF:Ag tertiles (Figure 2). With increasing FT4 
levels, the odds of being in the highest tertile of VWF:Ag and the lowest tertile of 
ADAMTS13 (category with highest thrombotic risk) were higher than the odds of being in 
the reference category (category with lowest thrombtic risk) (odds ratio, 4.1 per 1 ng/dl 
increase in FT4) (Figure 2).  
Thyroid function, coagulation factors, and cardiovascular disease 
In line with our previous data,(2) higher FT4 levels were associated with an increased risk of 
incident cardiovascular events (hazard ratio [HR], 2.01, 95% CI, 1.43 to 2.82, per 1 ng/dl 
increase; alternatively, HR, 1.14, 95% CI, 1.07 to 1.21, per 1 sd increase in FT4) and 
cardiovascular deaths (HR, 2.17, 95% CI, 1.53 to 3.09, per 1 ng/dl increase; alternatively, 
HR, 1.16, 95% CI, 1.08 to 1.23, per 1 sd increase in FT4) (Table 3). TSH was not associated 
with cardiovascular outcomes (Table 3). Higher VWF:Ag and fibrinogen levels were 
associated with an increased risk of incident cardiovascular events (HR, 1.08, 95% CI, 1.01 
to 1.15; HR, 1.09, 95% CI, 1.02 to 1.17, per 1 sd increase, respectively) and cardiovascular 
deaths (HR, 1.16, 95% CI, 1.09 to 1.24; HR, 1.23, 95% CI, 1.15 to 1.31, per 1 sd increase, 
respectively) (Table 3). Higher ADAMTS13 activity was associated with a decreased risk of 
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incident cardiovascular events and cardiovascular de ths (HR, 0.92, 95% CI, 0.86 to 0.99; 
HR, 0.89, 95% CI, 0.82 to 0.97, per 1 sd increase) (Table 3). The association of thyroid 
function with coagulation factors and cardiovascular outcomes remained similar or became 
stronger after restricting the analyses to euthyroid participants (Table 3). 
The effect of FT4 on incident cardiovascular events was minimally mediat d by 
fibrinogen (1.6%), but not by VWF:Ag or ADAMTS13 (Table 4). The effect of FT4 on 
cardiovascular deaths was partly mediated by VWF (5.4%) and fibrinogen (6.4%), but not by 
ADAMTS13. Taken together, VWF:Ag and fibrinogen mediated 10.0% of the effect of FT4 
on cardiovascular deaths (Table 4). The mediating effect of VWF:Ag and fibrinogen was 7% 
among euthyroid participants (Table 4).  
Discussion 
In this large population-based cohort study, higher FT4 levels were associated with higher 
VWF, lower ADAMTS13 activity, and higher fibrinogen levels, which indicate a 
procoagulant state. Participants with higher FT4 levels had an increased thrombotic risk. The 
associations were independent of cardiovascular risk factors, markers of inflammation and 
thyroid autoimmunity. VWF and fibrinogen mediated up to 10% of the association between 
FT4 and cardiovascular disease.   
To date, few population-based studies have investigated the association between 
categories of thyroid function and coagulation factors. High thyroid function has been linked 
to elevated levels of VWF and fibrinogen.(27,28) One cohort study showed that high FT4 
levels are associated with elevated VWF concentrations,(28) and another cohort study 
reported an association of low TSH levels with elevat d fibrinogen concentrations.(27) 
However, both studies were based on arbitrary categorizations of thyroid function, thus not 
being able to account for potential risk variations within categories. Besides VWF and 
fibrinogen, an additional factor of coagulation that could be influenced by thyroid function is 
the metalloprotease ADAMTS13. Yet, to our knowledge, no other cohort studies have 
explored the potential link between thyroid function and ADAMTS13 activity. Against this 
background, our study provides novel evidence on the association of thyroid function with 
coagulation, by focusing on the continuous range of TSH and FT4 levels, beyond the thyroid 
status categories. Our results support the hypothesis that the procoagulant effects of high 
thyroid hormones and the anticoagulant effects of low thyroid hormones are extended even 
within the normal reference range of thyroid function, as a continuum of effects.  
We accounted for several mechanisms that could explain the positive association of 
thyroid function with coagulation. Among others, can er and/or thyroid autoimmunity could 
alter both the circulating levels of thyroid hormones and coagulation factors.(29,30) 
However, the exclusion of cancer patients and the adjustment for TPOAb did not affect our 
results. Inflammation is another mechanism through which thyroid function could influence 
coagulation, but additional adjustments for levels of C reactive protein did not change our 
results. In line, a randomized crossover study found no effect of thyroid hormones on the 
expression of inflammation-related genes.(31) Taken together, these data suggest that cancer, 
thyroid autoimmunity and inflammation, do not explain our results.  
Several plausible mechanisms may explain the link between thyroid hormones and VWF. 
Low thyroid function is a well-known cause of acquired von Willebrand disease, which is 
characterized by low VWF antigen and/or activity. When induced by hypothyroidism, 
acquired von Willebrand disease is reversed after thyroid hormone replacement therapy, 
indicating a direct influence of thyroid hormones on VWF.(32) Most likely, thyroid 
hormones downregulate the synthesis of VWF in the endothelial cells, via controlling the 
transcription of the VWF gene.(10,33) In particular, n experimental study found that 
modulation of the VWF gene requires a prolonged exposure to triiodothyronine (ie, two 
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weeks).(10) This suggests that thyroid hormones can influence the synthesis of VWF not only 
via the nuclear thyroid hormone receptors, but alsovia affecting intermediate transcriptional 
receptors and/or via other mechanisms than receptor mediated gene expression. Previous 
studies indicate that thyroid hormones can induce the release of VWF via stimulation of the 
sympathetic nervous system.(34,35) Furthermore, our data suggests that thyroid hormones 
can attenuate the role of ADAMTS13 in cleaving the procoagulant VWF multimers into less 
procoagulant forms. Future studies need to confirm our results and further unravel the 
potential underlying mechanisms. 
The association of thyroid hormones with fibrinogen ca  be explained by the direct action 
of thyroid hormones on thyroid hormone receptors and corresponding response elements in 
the promoter region of the fibrinogen gene.(10,33) In a recent study, the administration of 
triiodothyronine resulted in a rapid modulation of fibrinogen gene, thus indicating that 
thyroid hormones have immediate effects on the synthesis of fibrinogen.(10) Variations in 
circulating thyroid hormone levels can also alter fib in clot structure and lysis.(36) 
Hypothyroidism has been associated with less compact fibrin networks, enhanced fibrinolysis 
and low fibrinogen levels; whereas hyperthyroidism has been associated with compact fibrin 
networks, resistance to fibrinolysis and high fibrinogen levels.(36,37) 
Our study showed that VWF and fibrinogen partly mediate the association of FT4 with 
cardiovascular disease. The observed proportion of mediation was up to 10%, which is 
meaningful given the multiple mechanisms through which thyroid hormones affect 
cardiovascular health. We found no evidence for a mediating role of ADAMTS13. Besides 
VWF and fibrinogen, other coagulation factors including factors VII, VIII, and IX, can also 
play a mediating role.(19,28,38,39) Unfortunately, data on these factors were not available in 
our study. If all relevant coagulation factors could be taken into account in our mediation 
analyses, the expected proportion of mediation related to coagulation may have been even 
higher than what we observed in our study.  
People with abnormal thyroid hormone levels, past thyroid disease, or using thyroid 
medications can be prone to fluctuating thyroid horm ne levels over time. The fluctuations 
could further interfere with the evaluation of cardiovascular risk. Instead, people with thyroid 
function within the normal reference range, without past thyroid disease and not using thyroid 
medications, have stable thyroid function over time with small intra-individual variation.(40) 
Importantly, our results remained statistically significant even after restricting the analyses to 
euthyroid participants, thus indicating the robustne s of our findings. 
Based on the negative feedback mechanism, the producti n of FT4 is tightly regulated by 
the hypothalamic-pituitary-thyroid axis, with a unique set point for each individual.(41) Our 
study consistently found an association of FT4 with coagulation factors. Though not 
statistically significant, the association of TSH with coagulation factors was generally in the 
expected opposite direction of FT4. Other population-based studies among middle-aged nd 
older adults have also reported that FT4, rather than TSH, is associated with an increased ri k 
of clinical outcomes.(2,4) This may be attributable to the aging process, which reduces the 
sensitivity of the pituitary gland to thyroid hormones.(42) In order to maintain the same FT4
levels, older subjects (such as the Rotterdam Study participants) may need different TSH 
levels compared with younger subjects. 
To our knowledge, this is the first population-based cohort study investigating the 
association of thyroid function with ADAMTS13, and the largest study investigating the 
association of thyroid function with VWF and fibrinogen. Moreover, this is the first study 
investigating the potential role of several coagulation factors in mediating the association 
between thyroid function and cardiovascular disease. Other major strengths are the long term 
follow-up (maximum follow-up time of almost 15 years), the comprehensive adjudication of 
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events, and the extensive information on potential confounders. Multiple sensitivity analyses 
provided consistent findings.  
Several limitations should also be mentioned. Thyroid function and coagulation 
measurements were performed at the same time, and we had no information on the temporal 
relationship of the association. Nevertheless, current evidence supports an effect of thyroid 
hormones on coagulation rather than vice-versa.(19) Furthermore, we had no data available 
on serum triiodothyronine FT3 levels. This did not allow us to calculate the FT3/ 4 ratio, 
which is considered a useful marker of peripheral thyroxine deiodination. However, we 
already had data available on TSH and FT4 levels, which represent the most commonly used 
measurements of thyroid function in clinical practice. Though we adjusted our analyses for 
multiple potential confounders, we cannot exclude the possibility of residual or unmeasured 
confounding. Lastly, the majority of our participants were white middle-aged and older 
adults. Therefore, the generalizability of our findings to other populations remains unclear. 
Conclusions 
High and high-normal FT4 levels among middle-aged and older adults were associated with a 
procoagulant state. VWF and fibrinogen explained up to 10% of the association between FT4 
and cardiovascular disease. The role of other potential mediators, including coagulation 
factors VII, VIII, and IX, needs to be examined by further investigations. Future prospective 
studies are also needed to confirm the temporal association between thyroid function and 
coagulation factors. 
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Figure 1. DAG for the association of free thyroxine, coagulation factors and 
cardiovascular outcomes A, free thyroxine; M, coagulation factor; Y, cardiovascular 
disease; C1, C2, C3, potential confounders 
Figure 2. Association of free thyroxine levels with combined ADAMTS 13 and VWF 
antigen. a. All participants (TN 5918) b. Euthyroid participants (TN 4646). Due to the 
biological interaction between VWF:Ag and ADAMTS13, multinomial logistic regression 
was performed to evaluate the association between FT4 levels and the nine combinations of 
VWF:Ag tertiles and ADAMTS13 tertiles, with lowest tertile of VWF:Ag and highest tertile 
of ADAMTS13 as the reference category. Analyses were adjusted for age, sex, cohort, 
smoking, alcohol intake, body mass index, diabetes, total cholesterol, triglycerides, systolic 
blood pressure, use of antihypertensive or lipid-lowering medications, use of anticoagulant 
medications, and  blood group. The plots indicate the odds of being in a specific coagulation 
category rather than in the reference category, per on  unit increase in FT4 levels. For 
example, for one unit increase in FT4 levels, the odds of being in the highest tertile of 
VWF:Ag and lowest tertile of ADAMTS13 (category with highest thrombotic risk) were 4.1 
times higher compared with the odds of being in the lowest tertile of VWF:Ag and highest 
tertile of ADAMTS13 (category with lowest thrombotic risk). Normal reference ranges of 
thyroid function were defined as serum TSH of 0.4 to .0 mIU/L and FT4 levels of 0.85 to 
1.95 ng/dL, after excluding thyroid medication users and participants with personal history of 
thyroid disease. *p<0.05; **p<0.0001 Abbreviations: OR, odds ratio; ADAMTS13, a 
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disintegrin and metalloprotease with thrombospondin motif repeats 13; VWF:Ag, von 
Willebrand factor antigen; Ref, reference category.  
Table 1. Baseline characteristics of 5918 participants                   
Age, years 69.1 ± 8.2 
Female 3356 (56.7) 
Smoking 
current 1068 (18.0)                          
former         2954 (49.9)   
never      1896 (32.0) 
TSH, mIU/L 1.8 [1.2-2.8] 
FT4, ng/dl 1.2 ± 0.2 
TPOAb positive 817 (13.3) 
Use of thyroid medication 177 (3.0) 
Thyroid surgery 131 (2.2) 
History of thyroid disease 498 (8.4) 
BMI, kg/m2 26.9 ± 3.9 
History of diabetes 774 (13.1) 
Total cholesterol, mmol/l 5.7 ± 0.9 
Triglycerides, mmol/l 1.5 ± 0.7 
Use of lipid-lowering medications 764 (12.9) 
Systolic blood pressure, mm Hg 143.2 ± 21.2 
Use of antihypertensive medications 1376 (23.3) 
Use of anticoagulant medications 1214 (20.5) 
Blood group O 2708 (45.8) 
C reactive protein, mg/l 1.8 [0.7-3.9] 
Prevalent CHD or stroke 691 (11.7) 
Prevalent cancer 289 (4.9) 
Fibrinogen, g/l 3.9 ± 0.9 
VWF:Ag, % 132 ± 58.4 
ADAMTS13 activity, % 91.6 ± 17.6 
Values for continuous variables are presented as men ± standard deviation or median [interquartile range]. 
Values for categorical variables are presented as number (percentage). Abbreviations: TSH, thyroid-stimulating 
hormone; FT4, free thyroxine; TPOAb, thyroid peroxidase antibodies (cutoff, 35 kU/ml); BMI, body-mass 
index; CHD, coronary heart disease; ADAMTS13, a disintegrin and metalloprotease with thrombospondin motif 
repeats 13; VWF:Ag, von Willebrand factor antigen.  
Table 2. Association between thyroid function and  Z scores of coagulation factors  
 All participants (TN 5918) Euthyroid participants* (TN 4646) 
 β (95% CI) β (95% CI) β (95% CI) β (95% CI) 
Model 1                                       Model 2 Model 1 Model 2         
VWF:Ag     
TSH -0.02 (-0.05; 0.01)    -0.03 (-0.06;-0.01)     0.00 (-0.05; 0.05) -0.02 (-0.07; 0.04) 
FT4  0.29 ( 0.16; 0.42)         0.34 ( 0.22; 0.47)  0.30 ( 0.12; 0.47)  0.34 ( 0.17; 0.50) 
ADAMTS13 activity  
TSH  0.02 (-0.01; 0.05)  0.00 (-0.03; 0.02)       0.06 ( 0.01; 0.12)  0.03 (-0.02; 0.09) 
FT4 -0.29 (-0.42;-0.16) -0.22 (-0.35;-0.09) -0.42 (-0.60;-0.25)     -0.33 (-0.50;-0.16) 
Fibrinogen  
TSH -0.03 (-0.06;-0.01) -0.02 (-0.05; 0.01) -0.04 (-0.09; 0.02) -0.01 (-0.06; 0.05) 
FT4  0.34 ( 0.21; 0.48)  0.26 ( 0.13; 0.39)  0.34 ( 0.16; 0.52)  0.25 ( 0.07; 0.42) 
Model 1:  age, sex, cohort; Model 2: Model 1, smoking, alcohol intake, body mass index, diabetes, total
cholesterol, triglycerides, systolic blood pressure, se of antihypertensive or lipid-lowering medications, use of 
anticoagulant medications, and  blood group.  βs of TSH are denoted per 1 unit increase of natural log 
transformed TSH (mIU/L). βs of FT4 are denoted per 1 unit increase in FT4 (ng/dL). *Normal reference ranges 
of thyroid function were defined as serum TSH of 0.4-4 0 mIU/L and FT4 levels of 0.85 to 1.95 ng/dL, after 
excluding thyroid medication users and participants wi h personal history of thyroid disease. Abbreviations: TN, 
total number; TSH, thyroid-stimulating hormone; FT4, free thyroxine; VWF:Ag, von Willebrand factor antigen; 
ADAMTS13, a disintegrin and metalloprotease with thrombospondin motif repeats 13. 
Table 3. Association of thyroid function and coagulation factors with incident cardiovascular 
events and deaths  
 CV events* CV deaths† 
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 HR (95% CI) HR (95% CI) 
All participants   
Events/Total number 857/5227 690/5918 
Thyroid function  
TSH  0.96 (0.89; 1.03) 0.96 (0.88; 1.04) 
FT4 2.01 (1.43; 2.82) 2.17 (1.53; 3.09) 
Coagulation factors (Z scores)‡ 
VWF:Ag 1.08 (1.01; 1.15) 1.16 (1.09; 1.24) 
ADAMTS13 0.92 (0.86; 0.99)     0.89 (0.82; 0.97)     
Fibrinogen 1.09 (1.02; 1.17) 1.23 (1.15; 1.31) 
Euthyroid participants#   
Events/Total number 675/4093 539/4646 
Thyroid function   
TSH 0.96 (0.82; 1.12) 0.88 (0.74; 1.05) 
FT4 2.79 (1.73; 4.49) 3.37 (2.01; 5.64) 
Coagulation factors (Z scores)‡ 
VWF:Ag 1.09 (1.01; 1.17) 1.15 (1.07; 1.24) 
ADAMTS13 0.90 (0.83; 0.98) 0.86 (0.78; 0.94) 
Fibrinogen 1.11 (1.03; 1.19) 1.21 (1.13; 1.31) 
Adjusted for age, sex, cohort, smoking, alcohol intake, body mass index, diabetes, total cholesterol, 
triglycerides, systolic blood pressure, use of antihypertensive or lipid-lowering medications, use of anticoagulant 
medications, and  blood group. 
HRs of TSH are denoted per 1 unit increase of natural log transformed TSH (mIU/L). HRs of FT4 are denoted 
per 1 unit increase in FT4 (ng/dL). *Participants with prevalent cardiovascular events were excluded from the 
analysis. †Additionally adjusted for prevalent cardiovascular disease. ‡Additionally adjusted for TSH and FT4. 
#Normal reference ranges of thyroid function were defined as serum TSH of 0.4 to 4.0 mIU/L and FT4 levels of 
0.85 to 1.95 ng/dL, after excluding thyroid medication users and participants with personal history of thyroid 
disease. Abbreviations: CV, cardiovascular; TSH, thyroid-stimulating hormone; FT4, free thyroxine; VWF:Ag, 
von Willebrand factor antigen; ADAMTS13, a disintegrin and metalloprotease with thrombospondin motif 
repeats 13. 
Table 4. Mediation analysis for the association of FT4 with cardiovascular events and deaths 
 Direct effect Indirect effect  PM (%) 
Potential mediator (Z scores of coagulation 
factors) 
     β  P value     β  P value  
All participants   
FT4 and incident cardiovascular events* (Events/Total number 857/5227)   
VWF:Ag 0.657  0.002 0.014  0.2   - 
ADAMTS13 0.661  0.001 0.011  0.2   - 
Fibrinogen 0.663  0.002 0.011  0.04  1.6 
VWF:Ag and fibrinogen 0.651  0.002 0.021  0.06   - 
FT4 and cardiovascular deaths† (Events/Total number 690/5918)   
VWF:Ag 0.642  0.004 0.037  0.02  5.4 
ADAMTS13 0.674  0.002 0.011  0.35  -  
Fibrinogen 0.629  0.004 0.043  0.006  6.4 
VWF:Ag and fibrinogen 0.600  0.007 0.066  0.001  10.0 
Euthyroid participants‡   
FT4 and incident cardiovascular events* (Events/Total number 675/4093)   
VWF:Ag 0.939 <0.001 0.0206 0.19 - 
ADAMTS13 0.938 <0.001 0.028 0.16 - 
Fibrinogen 0.945 <0.001 0.017 0.04 1.8 
VWF:Ag and fibrinogen 0.925  0.001 0.032 0.04 3.3 
FT4 and cardiovascular deaths† (Events/Total number 539/4646)   
VWF:Ag 0.993  0.001 0.040 0.3 3.9 
ADAMTS13 1.017        0.001 0.034       0.14 - 
Fibrinogen 0.986  0.001 0.046 0.03 4.5 
VWF:Ag and fibrinogen 0.945  0.002 0.071 0.008 7.0 
Adjusted for age, sex, cohort, smoking, alcohol intake, body mass index, diabetes, total cholesterol, 
triglycerides, systolic blood pressure, use of antihypertensive or lipid-lowering medications, use of anticoagulant 
medications, and blood group. *Participants with prevalent cardiovascular events were excluded from the 
analysis. †Additionally adjusted for prevalent cardiovascular disease. ‡Normal reference ranges of thyroid 
function were defined as serum TSH of 0.4 to 4.0 mIU/L and FT4 levels of 0.85 to 1.95 ng/dL, after excluding 
thyroid medication users and participants with personal history of thyroid disease. Abbreviations: FT4, free 
thyroxine; PM, proportion mediated; VWF:Ag, von Willebrand factor antigen.  
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